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ARTICLE INFO

ABSTRACT

Article type:

MYH9-related diseases (MYH9-RD) are clinically represented by thrombocytopenia, large
platelets, proteinuria and various degrees of renal dysfunction. We present a 25-year-old male with
thrombocytopenia, large platelets, renal dysfunction and proteinuria. Gene sequencing of whole exons
of MYH9 gene confirmed the diagnosis of MYH9-related disorder and revealed single nucleotide
polymorphisms (SNPs) in the introns 13 (rs3752462) and 14 (rs2413396) and a mutation in exon
26 of MYH9 gene. Our result supported the possibility of non-coding SNPs involvement in the
pathogenicity of the MYH9-RD disease and successful renal transplant in this patient.
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Implication for health policy/practice/research/medical education:
It is important to consider the possibility of macro-platelet-thrombocytopenia (MTCP) in patients with thrombocytopenia and renal
involvement, otherwise unnecessary therapeutic plasma exchange and immunosuppressive therapy may create deleterious side effects without
bringing any benefit.
Please cite this paper as: Zununi Vahed S, Niknafs B, Noshad H, Tolouian R, Mohajel Shoja M, Tolouian A, et al. Renal transplantation in a
patient with MHY9-related disease; a case report. J Nephropathol. 2021;10(x):exx. DOI: 10.34172/jnp.2021.xx.

Introduction
The combination of thrombocytopenia with renal
disease happens in various clinical scenarios including
thrombotic thrombocytopenia purpura, hemolytic-uremic
syndrome, drug-induced and cancer-related thrombotic
microangiopathy, systemic lupus erythematosus,
antiphospholipid syndrome and advanced liver disease
(1). Yet, macro-platelet-thrombocytopenia (MTCP) with
glomerular involvement is a rare combination that needs
clinical vigilance for its proper diagnosis and appropriate
management.
Historically, a combination of deafness, nephritis
and MTCP was first reported by Epstein et al in 1972,
as an autosomal dominant disorder. Subsequently,
*Corresponding author: Prof. Mohammadreza Ardalan,
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leukocyte inclusions and cataract were added to Epstein’s
description by Fechner, resulting in a new syndrome in
his name (2,3). However, hematologists were aware of two
other autosomal dominant MTCP syndromes named;
Sebastian and May-Hegglin anomaly syndromes. In the
first, leukocytes inclusion bodies were prominent, but
in both syndromes, the renal involvement and deafness
were absent. Later, these two distinct descriptions and
nominations were unified under the mutated MYH9
gene at chromosome 22q 11-13 loci. This gene encodes a
cytoskeletal contractile protein as the non-muscle myosin
heavy chain IIA (NMMHC-IIA). It resides at the end
of myosin molecule and interacts with actin fibrils in
podocytes, auditory Corti organ, leukocytes and platelets.
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MYH9-related disease (MYH9-RD) is a conclusive
and umbrella terminology for all those aforementioned
syndromes.
Case Presentation
Patient was a 25-year-old man who was consulted for
evaluation of nephrotic range proteinuria and hypertension.
He was diagnosed with idiopathic thrombocytopenic
purpura about nine years prior this admission. He had
received multiple courses of corticosteroid and intravenous
immuno-globulin therapy without any meaningful success
over those years. He underwent splenectomy at the age of
21 due to refractory thrombocytopenia. He was a farmer,
single and denied using tobacco, alcohol or exposure to
hazardous materials. Two of his second cousins had similar
histories of proteinuria and bleeding diathesis due to
refractory thrombocytopenia. Both had been on chronic
hemodialysis but had passed away years ago.
Laboratory examination revealed anemia [hemoglobin
10 g/dL], leukocytosis [WBC’s 17 000/μL] and
thrombocytopenia [PLT 31 000/μL]. The coagulation,
liver profiles and LDH were within normal range. Serum
creatinine was 4 mg/dL. Urine analysis showed protein
4+ and RBC 9-10/high power field (hpf ). 24-hour urine
protein was 3100 mg/day. Serologic markers including,
antinuclear antibody, anti-neutrophilic cytoplasmic
antibody, anti-dsDNA, anti-glomerular basement
membrane antibody, anti-cardiolipin Ab, HBsAg and
anti-HCV Ab, all were normal. Complement activating
factors of C3, C4 and CH50 and inhibitory factors of H
(CFH) and I (CFI) were in normal range. The activity of
ADAMTS 13 was 110 % (normal; 40-130). Peripheral
blood smear was remarkable for thrombocytopenia with
giant platelet with no schistocytes.
Abdominal ultrasound showed normal sized kidneys
with no hydronephrosis, liver was normal, splenectomy,
no ascites or para-aortic lymphadenopathy (Figure 1).
Bone marrow study was unremarkable. Ultrasound

Figure 1. Peripheral blood smear Giemsa staining (×40). Large
platelet (arrow) that are larger than polymorphonuclears (PMN)
in the fields.
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guided renal biopsy was performed with great caution.
The light microscopic was consistent with focal
segmental glomerulosclerosis (FSGS) (Figure 2) since
immunofluorescence study was negative. He was taking
angiotensin receptor blocker (losartan 25 mg twice daily)
and glucocorticoid (prednisolone 10 mg/d). During his
hospitalization, the glucocorticoid was stopped and he
continued with losartan, for proteinuria.
Gene sequencing of whole exons of MYH9 gene was
performed to confirm the diagnosis of MYH9-related
disorder. The DNA sample was negative for causative
point mutation, small deletion or duplication in the coding
and splice regions of MYH9 gene in high-throughput
sequencing. However, A c.1554+7A>G mutation in
intron 13 (SNP rs3752462), a c.1728+10G>A mutation
in intron 14 (SNP rs2413396) and a c.3429T>G mutation
in exon 26 were observed.
Then, the patient’s renal function gradually deteriorated
and hemodialysis was initiated. Soon after, the patient
received a living, unrelated-renal transplantation. Postoperative clinical course was complicated with bleeding
and large perinephric hematoma formation. Patient was
treated with platelet transfusion and drainage of periallograft blood collection. The patient was discharged
with normal renal allograft function. Three years after
transplantation, mild thrombocytopenia (PLT ~ 70 000)
without any bleeding episodes and stable renal allograft
function (serum creatinine; 1.2 mg/dL) were noted.
Discussion
In the present study, despite classic phenotypic presentations
of macro-platelet thrombocytopenia syndrome, none of
the previously reported genetic mutations in whole exons
of MYH9 gene were found. However, three SNPs were
observed in introns 13 (rs3752462), 14 (rs2413396) and
exon 26 (rs710181). Our finding was in concordance with
the study by Nelson et al, who found a strong association
between kidney disease and SNPs in introns 13 to 15

Figure 2. Glomerular staining (×40). (A) PAS and (B) H&E
staining. Mild peri-hilar sclerosis (FSGS) with open vascular spaces, without intracapillary or extracapillary proliferation. FSGS (focal segmental glomerulosclerosis).
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of MYH9 gene (4). SNP rs2413396 in exon 14 is a risk
variant and has the strongest recessive association with
FSGS development, as it modifies splice-determining
motifs of the NMMHCIIA protein; therefore, affects its
normal splicing and expression (4). Our results support
the possibility of non-coding SNPs involvement in the
pathogenicity of the MYH9-RD.
NMMHCIIA protein, coded by MYH9, is expressed
highly in mesangial cells and podocytes and has a key
role in the actin myosin contractile machine to preserve
the structure of the podocyte foot process. Disruption
of NMMHCIIA protein leads to podocyte collapse,
damage in glomerular filtration barrier and consequently,
proteinuria and glomerular sclerosis (5). A variety of
mutations comprising of 44 different changes is reported
in the MYH9 gene, mostly amino acids substitutions (6).
Missense mutations in MYH9-R influence the head or tail
domain of the NMHC IIA in most cases, while nonsense
or frameshift modifications lead to the deletion in a
C-terminal fragment of the protein (7, 8). It is suggested
that several MYH9 gene SNPs can predict kidney disease
(9,10). In 2008, MYH9 gene was considered as a risk
factor for non-diabetic end-stage renal disease and FSGS
in African (11,12). However, the idea soon shifted toward
the neighboring region on chromosome 22q12.3 and
apolipoprotein L1 (APOL1) risk variants (11-13).
Renal biopsy is a risky procedure in patients with
MTCP. The expected renal involvement in this condition
is FSGS and ours was the same. We do not recommend
conducting a renal biopsy due to risk of bleeding in
MTCP. Renal transplant is a valuable option in this
scenario. Although, there was a risk of bleeding, in our
case it was easy to manage. FSGS in this disease is caused
by podocytes MHY9-related structural damage and not
due to a circulating factor. Therefore, we did not expect for
proteinuria recurrence after renal transplant. Three years
post-renal transplant follow up patient did not show any
recurrence of proteinuria in our case. There are not several
reports of renal transplant in MHY9-related disease. We
speculate that patient survival should be shorter in this
population due to underlying disease. Since, the renal
allograft has normal podocyte structure; therefore, we are
assuming that 5-year or even 10-year renal/graft survival
should be equal or even better than its control.
Conclusion
MYH9-related diseases are rare clinical syndromes. It is a
structural abnormality of non-muscle myosin IIA heavy
chain. Its clinical presentations are complex and ranging
from podocytopathy to platelet structural impairment.
Lack of knowledge about this abnormality may lead to
misdiagnosis and mismanagement of the disease. This is
a rare case report of a successful renal transplantation in a
www.nephropathol.com

MYH9-RD patient.
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